venetoclax,acalabrutinib,obinutuzumab
astrazeneca,abbvie,roche
['cll', 'obinu', 'venetoclax', 'acalabrutinib']
a study by christine ryan, md, and highlights the effectiveness of the acalabrutinib, venetoclax, obinutuzumab combination in frontline treatment for #cll. #ash22 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090